Literature DB >> 21479875

Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.

Adele Caldarella1, Emanuele Crocetti, Simonetta Bianchi, Vania Vezzosi, Carmelo Urso, Mauro Biancalani, Marco Zappa.   

Abstract

The aim of this study is to evaluate the prognostic values of some biological parameters in a population based series of female breast cancer patients. Through the Tuscan Cancer Registry all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Molecular subtypes were analyzed defined by immunohistochemical markers, by age, tumor size, lymph node status, histotype, grade of differentiation and proliferative marker. Out of 1487 patients 70.3% were luminal A subtype (ER/PR + HER2-), 15.6% luminal B (ER/PR + HER2+), 8.1% triple negative (ER/PR-HER2-), 6.0% HER2+ (ER/PR-HER2+); the 3 year survival rates were 93.3%, 89.5%, 86.3%, 82.7% respectively (p < 0.001). Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of molecular classification. Our study revealed significant differences in clinicopathological characteristics among breast cancer molecular subtypes and confirmed their prognostic independent role.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479875     DOI: 10.1007/s12253-011-9381-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

1.  Human epidermal growth factor receptor 2 testing: where are we?

Authors:  Pradip De; Brian R Smith; Brian Leyland-Jones
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

2.  Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.

Authors:  Mary Jo Lund; Ebonee N Butler; Brionna Y Hair; Kevin C Ward; Judy H Andrews; Gabriella Oprea-Ilies; A Rana Bayakly; Ruth M O'Regan; Paula M Vertino; J William Eley
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

3.  Differences in risk factors for breast cancer molecular subtypes in a population-based study.

Authors:  Xiaohong R Yang; Mark E Sherman; David L Rimm; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Stephen M Hewitt; William F Anderson; Neonila Szeszenia-Dabrowska; Alicja Bardin-Mikolajczak; Witold Zatonski; Richard Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanislaw Lukaszek; Radzisaw Kordek; Montserrat García-Closas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

4.  Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Authors:  Rohit Bhargava; Sushil Beriwal; David J Dabbs; Umut Ozbek; Atilla Soran; Ronald R Johnson; Adam M Brufsky; Barry C Lembersky; Gretchen M Ahrendt
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

5.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

6.  Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland.

Authors:  A Spitale; P Mazzola; D Soldini; L Mazzucchelli; A Bordoni
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

Review 7.  Current issues in ER and HER2 testing by IHC in breast cancer.

Authors:  Allen M Gown
Journal:  Mod Pathol       Date:  2008-05       Impact factor: 7.842

8.  Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.

Authors:  Marilyn L Kwan; Lawrence H Kushi; Erin Weltzien; Benjamin Maring; Susan E Kutner; Regan S Fulton; Marion M Lee; Christine B Ambrosone; Bette J Caan
Journal:  Breast Cancer Res       Date:  2009-05-22       Impact factor: 6.466

9.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

10.  Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Authors:  Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

View more
  22 in total

1.  Response.

Authors:  William F Anderson; Philip S Rosenberg; Aleix Prat; Charles M Perou; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2015-02-24       Impact factor: 13.506

2.  Mammographic and clinicopathological features of triple-negative breast cancer.

Authors:  B Gao; H Zhang; S-D Zhang; X-Y Cheng; S-M Zheng; Y-H Sun; D-W Zhang; Y Jiang; J-W Tian
Journal:  Br J Radiol       Date:  2014-04-15       Impact factor: 3.039

3.  Aryl hydrocarbon receptor in breast cancer—a newly defined prognostic marker.

Authors:  Ryoko Saito; Yasuhiro Miki; Shuko Hata; Kiyoshi Takagi; Shinya Iida; Yuki Oba; Katsuhiko Ono; Takanori Ishida; Takashi Suzuki; Noriaki Ohuchi; Hironobu Sasano
Journal:  Horm Cancer       Date:  2014-02       Impact factor: 3.869

4.  Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.

Authors:  Laura C Collins; Shari Gelber; Jonathan D Marotti; Sarah White; Kathryn Ruddy; Elena F Brachtel; Lidia Schapira; Steven E Come; Virginia F Borges; Pepper Schedin; Ellen Warner; Taylor Wensley; Rulla M Tamimi; Eric P Winer; Ann H Partridge
Journal:  Oncologist       Date:  2015-05-29

5.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

6.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Authors:  Veronique M Neumeister; Valsamo Anagnostou; Summar Siddiqui; Allison Michal England; Elizabeth R Zarrella; Maria Vassilakopoulou; Fabio Parisi; Yuval Kluger; David G Hicks; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2012-10-22       Impact factor: 13.506

7.  Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study.

Authors:  Ching-Hung Lin; Po-Ya Chuang; Chun-Ju Chiang; Yen-Shen Lu; Ann-Lii Cheng; Wen-Hung Kuo; Chiun-Sheng Huang; Mei-Shu Lai; San-Lin You; Chao-Hsiun Tang
Journal:  Oncologist       Date:  2014-05-07

8.  Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.

Authors:  A Caldarella; D Puliti; E Crocetti; S Bianchi; V Vezzosi; P Apicella; M Biancalani; A Giannini; C Urso; F Zolfanelli; E Paci
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-09       Impact factor: 4.553

9.  Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer.

Authors:  Megan Greally; Jennifer Kielty; Geoffrey A Watson; Geoffrey Das; Christina Malouf; Lynda McSorley; Niamh Coleman; Cecily Quinn; Enda W McDermott; Giuseppe Gullo; John Crown; Ruth S Prichard; Catherine M Kelly; Janice M Walshe
Journal:  Ir J Med Sci       Date:  2018-05-15       Impact factor: 1.568

10.  Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.

Authors:  Pamela Minicozzi; Francesca Bella; Angela Toss; Adriano Giacomin; Mario Fusco; Maurizio Zarcone; Rosario Tumino; Fabio Falcini; Rosaria Cesaraccio; Giuseppa Candela; Francesco La Rosa; Massimo Federico; Milena Sant
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.